ANNX250117P3000
- 0.90
- 0.000.00%
Annexon Newsroom
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $12 to $30
Annexon Biosciences' ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential
Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment
Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome
Express News | Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)
Annexon Insider Buyers Pleased With US$571k Return On Investment
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors With ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
Express News | Annexon Inc : JP Morgan Cuts Target Price to $9 From $11
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Express News | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Express News | Cantor Fitzgerald Reiterates Overweight on Annexon
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $30
A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $14 to $30
Annexon Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Annexon Analyst Ratings
Annexon | 10-Q: Q3 2024 Earnings Report
Annexon Biosciences: Buy Rating Backed by Promising Data Releases and Strategic Long-term Potential
Annexon | 8-K: Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Annexon Reports Q3 EPS (25c), Consensus (27c)